Immunovant Inc
IMVT · NASDAQ
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Market Data
Price
$33.44
-0.18 (-0.54%)
Market Cap$6.90B
P/E Ratio—
EPS$—
52W High$36.29
52W Low$14.32
Beta0.80
Data from Finnhub · Updated Jun 16, 2026